Aplastic anaemia (AA), a atypical disorder resulting in progressive reduction of development of blood cells which is due to repression of bone marrow. Pathogenetic mechanism is the trigger-related abnormal T cell response which leads to the increased production of cytokines that inhibit bone marrow. Immunosuppressive treatment (IST) confirms immuno-mediated pathogenesis by using cyclosporine A + antithymocyte globulin, which can be represented as the first-choice therapy due to non-availability of matched sibling donor (MSD) for transplantation in individuals less 40 years. Intractable AA or refracted AA generally characterized by, lack of response to first line IST by using ATG and cyclosporine resulted in the occurrence of stern cytopenias within 6 months after treating with IST. Hematopoietic stem cell transplantation is option of management when intractable AA individuals are healthy and when they have a suitably corresponding donor, either a sibling (usually greater than 40-50 years) or distinct contributor. Individuals who do not have a completely corresponding contributor must be taken into consideration for managing with 2nd course of ATG all along with cyclosporine, even though response in the intractable setting is only ∼30% to 35%. Improvement may also take place by using medicaments like alemtuzumab or eltrombopag in intractable AA. Recent advances in the treatment of AA including blood transfusions and allied issues, immunosuppressant’s, bone marrow stimulants, stem cell transplant, antibiotics, antivirals and management of refractory AA are briefly covered in present review.